Delineation of a conserved arrestin-biased signaling repertoire in vivo

Molecular Pharmacology

Volumn 87, Issue 4, 2015, Pages 706-717

  Maudsley, Stuart ^a   Martin, Bronwen ^a   Gesty Palmer, Diane ^b   Cheung, Huey ^c   Johnson, Calvin ^c   Patel, Shamit ^a   Becker, Kevin G ^a   Wood, William H ^a   Zhang, Yongqing ^a   Lehrmann, Elin ^a   Luttrell, Louis M ^d,e  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[7-34]; RETINA S ANTIGEN; UNCLASSIFIED DRUG; ARRESTIN3; PARATHYROID HORMONE; PARATHYROID HORMONE (7-34); PARATHYROID HORMONE RECEPTOR 1; PEPTIDE FRAGMENT; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; GENE EXPRESSION; GENE ONTOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; AGONISTS; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGY; BOVINE; C57BL MOUSE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; SPECIES DIFFERENCE;

ANIMALS; ARRESTINS; CATTLE; COMPUTATIONAL BIOLOGY; HUMANS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SPECIFICITY; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RECEPTOR, PARATHYROID HORMONE, TYPE 1; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84965189534     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.095224     Document Type: Article

References (48)

1. Appleton KM, Lee M-H, Alele C, Alele C, Luttrell DK, Peterson YK, Morinelli TA, and Luttrell LM (2013) Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity. Methods Enzymol 522:229-262.
2. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, and Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286: 2495-2498.
3. Bonnans C, Flacelière M, Grillet F, Dantec C, Desvignes JP, Pannequin J, Severac D, Dubois E, Bibeau F, and Escriou V et al. (2012) Essential requirement for β-arrestin2 in mouse intestinal tumors with elevated Wnt signaling. Proc Natl Acad Sci USA 109:3047-3052.
4. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, and DuBois RN (2006) Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103:1492-1497.
5. Carlsson G (2009) Topology and data. Bull Am Math Soc 46:255-308.
6. Chadwick W, Zhou Y, Park SS, Wang L, Mitchell N, Stone MD, Becker KG, Martin B, and Maudsley S (2010) Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS ONE 5:e14352.
7. Christensen GL, Kelstrup CD, Lyngsø C, Sarwar U, Bøgebo R, Sheikh SP, Gammeltoft S, Olsen JV, and Hansen JL (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9:1540-1553.
8. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
9. Chun KS, Lao HC, Trempus CS, Okada M, and Langenbach R (2009) The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. Carcinogenesis 30: 1620-1627.
10. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, and Chellappan S (2006) Nicotine induces cell proliferation by beta-arrestinmediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 116: 2208-2217.
11. Fereshteh M, Ito T, Kovacs JJ, Zhao C, Kwon HY, Tornini V, Konuma T, Chen M, Lefkowitz RJ, and Reya T (2012) β-Arrestin2 mediates the initiation and progression of myeloid leukemia. Proc Natl Acad Sci USA 109:12532-12537.
12. Galandrin S and Bouvier M (2006) Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70: 1575-1584.
13. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, and Luttrell LM et al. (2006) Distinct β-arrestin-and G proteindependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864.
14. Gesty-Palmer D, Flannery P, Yuan L, Spurney R, Lefkowitz RJ, and Luttrell LM (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1:1ra1.
15. Gesty-Palmer D, Yuan L, Martin B, Wood WH, 3rd, Lee MH, Janech MG, Tsoi LC, Zheng WJ, Luttrell LM, and Maudsley S (2013) β-arrestin-selective G proteincoupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol 27:296-314.
16. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
17. Kenakin T (2007) Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72:1393-1401.
18. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
19. Kendall RT, Strungs EG, Rachidi SM, Lee MH, El-Shewy HM, Luttrell DK, Janech MG, and Luttrell LM (2011) The β-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1, Ile4, Ile8]angiotensin II regulates a robust G proteinindependent signaling network. J Biol Chem 286:19880-19891.
20. Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie Z, Messias NC, Benovic JL, and Daaka Y (2009) Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci USA 106:9379-9384.
21. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, Mills GB, Babwah AV, and Bhattacharya M (2009) Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7:1064-1077.
22. Liu H, Long J, Zhang PH, Li K, Tan JJ, Sun B, Yu J, Tu ZG, and Zou L (2011) Elevated β-arrestin1 expression correlated with risk stratification in acute lymphoblastic leukemia. Int J Hematol 93:494-501.
23. Liu JJ, Horst R, Katritch V, Stevens RC, and Wüthrich K (2012) Biased signaling pathways in b2-adrenergic receptor characterized by 19F-NMR. Science 335: 1106-1110.
24. Lum PY, Singh G, Lehman A, Ishkanov T, Vejdemo-Johansson M, Alagappan M, Carlsson J, and Carlsson G (2013) Extracting insights from the shape of complex data using topology. Sci Rep 3:1236.
25. Luttrell LM (2014) Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. Mol Endocrinol 28:281-294.
26. Luttrell LM, Ferguson SSG, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, and Luttrell DK et al. (1999) β-arrestin-dependent formation of b2 adrenergic receptor-Src protein kinase complexes. Science 283: 655-661.
27. Luttrell LM and Gesty-Palmer D (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62:305-330.
28. Luttrell LM and Kenakin TP (2011) Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol 756:3-35.
29. Mahon MJ, Cole JA, Lederer ED, and Segre GV (2003) Na1/H1 exchanger-regulatory factor 1 mediates inhibition of phosphate transport by parathyroid hormone and second messengers by acting at multiple sites in opossum kidney cells. Mol Endocrinol 17:2355-2364.
30. Mahon MJ, Donowitz M, Yun CC, and Segre GV (2002) Na1/H1 exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 417:858-861.
31. Martin B, Chadwick W, Cong WN, Pantaleo N, Daimon CM, Golden EJ, Becker KG, Wood WH, 3rd, Carlson OD, and Egan JM et al. (2012a) Euglycemic agentmediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy. J Biol Chem 287: 31766-31782.
32. Martin B, Chadwick W, Yi T, Park SS, Lu D, Ni B, Gadkaree S, Farhang K, Becker KG, and Maudsley S (2012b) VENNTURE-a novel Venn diagram investigational tool for multiple pharmacological dataset analysis. PLoS ONE 7:e36911.
33. Martin B, Chen H, Daimon CM, Chadwick W, Siddiqui S, and Maudsley S (2013) Plurigon: three dimensional visualization and classification of high-dimensionality data. Front Physiol 4:190.
34. Maudsley S, Martin B, and Luttrell LM (2005) The origins of diversity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther 314:485-494.
35. Maudsley S, Patel SA, Park SS, Luttrell LM, and Martin B (2012) Functional signaling biases in G protein-coupled receptors: Game theory and receptor dynamics. Mini Rev Med Chem 12:831-840.
36. Maudsley S, Siddiqui S, and Martin B (2013) Systems analysis of arrestin pathway functions. Prog Mol Biol Transl Sci 118:431-467.
37. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, and Laurila E et al. (2003) PGC-1a-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273.
38. Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, and Watson DK (2008) Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res 68:4097-4104.
39. Nicolau M, Levine AJ, and Carlsson G (2011) Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. Proc Natl Acad Sci USA 108:7265-7270.
40. Pi M, Oakley RH, Gesty-Palmer D, Cruickshank RD, Spurney RF, Luttrell LM, and Quarles LD (2005) Beta-arrestin-and G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol Endocrinol 19:1078-1087.
41. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, and Bagnato A (2009) Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106:2806-2811.
42. Sardiu ME, Gilmore JM, Groppe BD, Herman D, Ramisetty SR, Cai Y, Jin J, Conaway RC, Conaway JW, and Florens L et al. (2014) Conserved abundance and topological features in chromatin-remodeling protein interaction networks. EMBO Rep 16:116-126.
43. Saulière A, Bellot M, Paris H, Denis C, Finana F, Hansen JT, Altié MF, Seguelas MH, Pathak A, and Hansen JL et al. (2012) Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol 8:622-630.
44. Shenoy SK and Lefkowitz RJ (2011) β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32:521-533.
45. Ureña P, Kong XF, Abou-Samra AB, Jüppner H, Kronenberg HM, Potts JT, Jr, and Segre GV (1993) Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 133:617-623.
46. Watts DJ and Strogatz SH (1998) Collective dynamics of 'small-world' networks. Nature 393:440-442.
47. Whalen EJ, Rajagopal S, and Lefkowitz RJ (2011) Therapeutic potential of β-arrestin-and G protein-biased agonists. Trends Mol Med 17:126-139.
48. Wei H, Ahn S, Shenoy SK, Karnik S, Hunyady L, Luttrell LM, and Lefkowitz RJ (2003) Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100:10782-10787.